Meanwhile, the use of the most effective drugs at the earliest stage of treatment contributes to longer remission of the disease and may extend their survival.
The report was created on the initiative of HematoKoalicja, which included four patient organizations (Alivia Oncology Foundation, Wiesława Adamiec Carita Foundation, PARS - Polskie Amazonki Ruch Społeczny and OnkoCafe Foundation - Better Together), in cooperation with the research company HTA Registry. Its authors focused on patients with multiple myeloma and chronic lymphocytic leukemia.
The survey presented in the report, which was conducted among patients with hematopoietic malignancies and their caregivers, shows that 32 percent. patients and 46 percent. their guardians decide ...
Content locked
To gain access to the complete English section of the Medexpress.pl, kindly reach out to us at [email protected].
